Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 11:11:669-680.
doi: 10.2147/CMAR.S187316. eCollection 2019.

Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis

Mingmin Shi  1 , Lei Chen  2 , Yangxin Wang  1 , Wei Wang  1 , Yujie Zhang  1 , Shigui Yan  1
Affiliations

Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis

Mingmin Shi et al. Cancer Manag Res. .

Abstract

Background: Giant cell tumor of bone (GCTB) is a locally aggressive tumor, and its postoperative recurrence remains a problem. The present meta-analysis aimed to analyze the effect of bisphosphonates (BPs) on local recurrence of GCTB.

Methods: Seven case-control studies were included by computerized searches of bibliographic databases (PubMed, AMED, EMBASE, the Cochrane library, ISI Web of Science, and China National Knowledge Infrastructure). The pooled adjusted ORs were calculated to evaluate the local recurrence of GCTB.

Results: The BP group presented significantly lower total local recurrence rate than the control group in GCTB (P<0.01). Subgroup analysis shows BP group presented significantly lower local recurrence than the control group in GCTB with different tumor grades (P<0.05). In patients who underwent intralesional curettage, a significantly lower local recurrence rate was found in the BP group compared with the control group (P<0.01), but no significance was found for patients who underwent wide resection (P=0.16). None of the included studies described severe adverse effects related to BPs.

Conclusion: The results confirmed the effect of BPs on reducing the local recurrence of GCTB, and the effect is not influenced by the tumor grades. BPs are benefit for the patients who underwent intralesional curettage but not recommended for those who underwent wide resection.

Keywords: bisphosphonates; giant cell tumor of bone; local recurrence; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of the selection strategy and inclusion/exclusion criteria for the present meta-analysis.
Figure 2
Figure 2
Forest plots for the effect of BPs on total postoperative recurrence in patients with GCTB. Abbreviations: BPs, bisphosphonates; GCTB, giant cell tumor of bone.
Figure 3
Figure 3
Forest plots for subgroup analysis for the effect of BPs on postoperative recurrence in patients with GCTB with different tumor grades. Notes: (A) For patients with stage I–II GCTB, a significant difference in local recurrence rate was found between the BP group and the control group (P<0.05). (B) For patients with stage III GCTB, a significant difference in local recurrence rate was found between the BP group and the control group. Abbreviations: BPs, bisphosphonates; GCTB, giant cell tumor of bone.
Figure 4
Figure 4
Forest plots for subgroup analysis for the effect of BPs on postoperative recurrence in patients with GCTB with different surgical procedures. Notes: (A) For patients who underwent intralesional curettage, a significant difference in local recurrence rate was found between the BP group and the control group (P<0.01). (B) For patients who underwent wide resection, there was no significant difference in local recurrence rate between the BP group and the control group (P=0.16). Abbreviations: BPs, bisphosphonates; GCTB, giant cell tumor of bone.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Thangaraj R, Grimer RJ, Carter SR, Stirling AJ, Spilsbury J, Spooner D. Giant cell tumour of the sacrum: a suggested algorithm for treatment. Eur Spine J. 2010;19(7):1189–1194. - PMC - PubMed
    1. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69(1):106–114. - PubMed
    1. Kamal AF, Simbolon EL, Prabowo Y, Hutagalung EU. Wide resection versus curettage with adjuvant therapy for giant cell tumour of bone. J Orthop Surg. 2016;24(2):228–231. - PubMed
    1. Gaston CL, Bhumbra R, Watanuki M, et al. Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg Br. 2011;93-B(12):1665–1669. - PubMed
    1. Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):969–978. - PubMed